ArticleThe European respiratory journal2012
Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk.
Article in The European respiratory journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Differential yield of universal versus selective drug susceptibility testing of patients with tuberculosis in high-burden countries: a systematic review and meta-analysis.BMJ global health · 2020Pooled it
- Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.International journal of molecular sciences · 2016Pooled it
- Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates.Lancet (London, England) · 2014Pooled it
- Pooled it
- Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes.The European respiratory journal · 2013Pooled it
- Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis.The European respiratory journal · 2013Pooled it
- Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones.The European respiratory journal · 2012Pooled it
- Development of Isoniazid-Pyrazole Hybrids as Potential Antitubercular Agents.International journal of molecular sciences · 2026Article
- Panduratin A Induces Autophagy Through AMPK Activation Independent of mTOR Inhibition and Restricts Mycobacterium tuberculosis in Host Macrophages.Molecular microbiology · 2025Article
- Oligomerisation of Ku from Mycobacterium tuberculosis promotes DNA synapsis.Nature communications · 2025Article
- Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Article
- "East" in Europe-Health Dimension through the Lens of the UKInternational journal of environmental research and public health · 2021Article
- Tuberculosis Drug Susceptibility, Treatment, and Outcomes for Belarusian HIV-Positive Patients with Tuberculosis: Results from a National and International Laboratory.Tuberculosis research and treatment · 2021Article
- The Research Progress in Immunotherapy of Tuberculosis.Frontiers in cellular and infection microbiology · 2021Review
- Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data.PLoS medicine · 2020Observational
- Machine learning and structural analysis of Mycobacterium tuberculosis pan-genome identifies genetic signatures of antibiotic resistance.Nature communications · 2018Article
- Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.The Lancet. Infectious diseases · 2018Article
- Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Frontiers in cellular and infection microbiology · 2018Review
- Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study.The Journal of infection · 2018Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to anti-tuberculosis (TB) medicines is a major public health threat in most countries of the former Soviet Union. As no representative and quality-assured information on the magnitude of this problem existed in Belarus, a survey was conducted in the capital city of Minsk. Between November 2009 and December 2010, 156 consecutively diagnosed new and 68 previously treated culture-positive TB patients residing in Minsk were enrolled in the survey. Mycobacterium tuberculosis isolates were obtained from each patient and tested for susceptibility to first- and second-line anti-TB drugs. Multidrug-resistant (MDR)-TB was found in 35.3% (95% CI 27.7-42.8) of new patients and 76.5% (95% CI 66.1-86.8) of those previously treated. Overall, nearly one in two patients enrolled had MDR-TB. Extensively drug-resistant TB was reported in 15 of the 107 MDR-TB patients (14.0%, 95% CI 7.3-20.7). Patients <35 yrs of age have shown a two times higher odds ratio of multidrug-resistant TB than those aged >35 yrs. The findings of this survey in Minsk city are alarming and represent the highest proportions of MDR-TB ever recorded in the world. This study greatly contributes to the understanding of the burden of drug-resistant TB in urban areas of Belarus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.